Welcome to our dedicated page for Akari Therapeutics Plc news (Ticker: AKTX), a resource for investors and traders seeking the latest updates and insights on Akari Therapeutics Plc stock.
Akari Therapeutics plc (NASDAQ: AKTX) is an oncology biotechnology company whose news flow centers on the development of its PH1-based antibody–drug conjugates (ADCs). Company updates frequently highlight progress with its lead Trop2-targeting ADC, AKTX-101, and the broader PH1 spliceosome-modulating payload platform designed to disrupt RNA splicing in cancer cells and activate immune responses.
Investors following AKTX news can expect regular announcements on preclinical data, particularly in hard-to-treat solid tumors such as KRAS-mutant pancreatic ductal adenocarcinoma, urothelial (bladder) cancer, and gastric cancer. Akari’s releases often describe new efficacy and safety findings for AKTX-101, including comparisons with ADCs that use traditional payloads and exploratory work on synergy with checkpoint inhibitors.
Another recurring news theme is platform and pipeline development. Akari reports on the evolution of its ADC discovery platform, the advancement of additional candidates like AKTX-102 for GI and lung cancers, and scientific engagement through conference presentations and virtual investor segments such as its “CEO Corner” and “What This Means” features.
On the corporate side, Akari’s news includes financing transactions, such as registered direct offerings, private placements with warrants, and note exchanges that the company states are intended to fund research and development, working capital, and general corporate purposes. Updates on manufacturing partnerships, including GMP manufacturing of AKTX-101 with WuXi XDC, and disclosures related to Nasdaq listing requirements also appear in its news stream.
For readers tracking oncology innovation and early-stage ADC pipelines, the AKTX news page offers a focused view of how Akari is progressing its PH1 payload technology, preparing for potential clinical trials, and managing the capital and governance steps that support its development plans.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Akari Therapeutics, Plc (Nasdaq: AKTX) announced it has been granted an additional 180-day compliance period by Nasdaq, extending the deadline to regain compliance with the minimum bid price requirement until October 23, 2023. To maintain its listing, Akari must keep a minimum closing bid price of $1.00 per share for at least ten consecutive business days. There is no immediate impact on the company’s Nasdaq listing, and its American Depository Shares will continue to be traded. Akari is focused on developing advanced therapies for autoimmune diseases, with lead investigational asset nomacopan undergoing Phase 3 trials for pediatric HSCT-TMA. The company holds Orphan Drug and Fast Track designations from the FDA for this treatment.
On April 14, 2023, Akari Therapeutics (Nasdaq: AKTX) announced a virtual key opinion leader event scheduled for May 22, 2023, at 2 PM ET. This session will delve into the treatment landscape for geographic atrophy (GA) and the potential of long-acting PAS-nomacopan, an investigational therapy aimed at addressing significant unmet needs in this area. The event will feature Dr. Elias Reichel from Tufts University School of Medicine, who will discuss the development program for PAS-nomacopan. Following the presentations, a live Q&A session will be held. Interested individuals can register for the event through the provided link, and a replay will be available on the Akari website.
Akari Therapeutics is focused on developing advanced therapies for autoimmune and inflammatory diseases, with nomacopan as its lead asset. The company has received various designations for nomacopan related to its pediatric healthcare applications.
Akari Therapeutics, Plc (Nasdaq: AKTX) is set to participate in ARVO 2023 from April 23 to 27 in New Orleans. The event gathers around 10,000 professionals in vision research to discuss advancements in the field. Akari’s primary focus is on its investigational drug, nomacopan, a bispecific inhibitor targeting complement C5 and leukotriene B4, currently in pre-clinical development for geographic atrophy. Akari is also advancing nomacopan through a Phase 3 trial for pediatric HSCT-TMA, supported by FDA designations including Orphan Drug and Fast Track. The company aims to connect with researchers and potential partners at ARVO 2023 to drive innovation in autoimmune and inflammatory disease therapies.
Akari Therapeutics (Nasdaq: AKTX) announced a case study presentation titled Clinical Response to Nomacopan in the Paediatric HSCT-TMA Setting, scheduled for April 23, 2023, during the European Society for Blood and Marrow Transplantation (EBMT) in Paris. Nomacopan, an investigational bispecific inhibitor, is currently in Phase 3 clinical trials targeting pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). The company plans to advance into pivotal Part B trials later this year. Akari holds multiple FDA designations for nomacopan and is developing it for both pediatric and adult indications.